Breast cancer growth prevention by statins.
暂无分享,去创建一个
E. Petricoin | L. Liotta | L. Esserman | C. Benz | F. Baehner | S. Benz | Yamei Zhou | C. Marx | M. Campbell | M. Winters | Anjali S. Kumar | M. Lobo | M. Shoemaker | Elizabeth Borman | K. Adduci
[1] S. Bonovas,et al. Use of statins and breast cancer: a meta-analysis of seven randomized clinical trials and nine observational studies. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] Vikas Khurana,et al. Statins to reduce breast cancer risk: A case control study in U.S. female veterans , 2005 .
[3] Urs Eppenberger,et al. Activation of nuclear factor-κB (NFκB) identifies a high-risk subset of hormone-dependent breast cancers , 2005 .
[4] M. Katz. Therapy Insight: potential of statins for cancer chemoprevention and therapy , 2005, Nature Clinical Practice Oncology.
[5] Henk-Jan Guchelaar,et al. Effects of statins and farnesyltransferase inhibitors on the development and progression of cancer. , 2004, Cancer treatment reviews.
[6] G. Thorgeirsson,et al. Mortality and incidence of cancer during 10-year follow-up of the Scandinavian Simvastatin Survival Study (4S) , 2004, The Lancet.
[7] Debajit K. Biswas,et al. NF-κB activation in human breast cancer specimens and its role in cell proliferation and apoptosis , 2004 .
[8] Henk-Jan Guchelaar,et al. The risk of cancer in users of statins. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] R. Paoletti,et al. Safety of Statins: Focus on Clinical Pharmacokinetics and Drug Interactions , 2004, Circulation.
[10] S. Heckbert,et al. The association between 3‐hydroxy‐3‐methylglutaryl conenzyme A inhibitor use and breast carcinoma risk among postmenopausal women , 2004, Cancer.
[11] T. Kawabe,et al. Different Effects of Point Mutations within the B-Raf Glycine-Rich Loop in Colorectal Tumors on Mitogen-Activated Protein/Extracellular Signal-Regulated Kinase Kinase/Extracellular Signal-Regulated Kinase and Nuclear Factor κB Pathway and Cellular Transformation , 2004, Cancer Research.
[12] M. Cortés,et al. ATM and the Catalytic Subunit of DNA-Dependent Protein Kinase Activate NF-κB through a Common MEK/Extracellular Signal-Regulated Kinase/p90rsk Signaling Pathway in Response to Distinct Forms of DNA Damage , 2004, Molecular and Cellular Biology.
[13] M. Karin,et al. NF-κB in Mammary Gland Development and Breast Cancer , 2003, Journal of Mammary Gland Biology and Neoplasia.
[14] C. Benz,et al. Age-Dependent Changes in Breast Cancer Hormone Receptors and Oxidant Stress Markers , 2002, Breast Cancer Research and Treatment.
[15] L. Esserman,et al. Breast cancer inhibition by statins. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] Y. Oka,et al. MEK kinase 1 mediates the antiapoptotic effect of the Bcr-Abl oncogene through NF-κB activation , 2003, Oncogene.
[17] Katie L Stone,et al. Lipid-lowering drug use and breast cancer in older women: a prospective study. , 2003, Journal of women's health.
[18] S. Merajver,et al. Atorvastatin prevents RhoC isoprenylation, invasion, and metastasis in human melanoma cells. , 2003, Molecular cancer therapeutics.
[19] R. Parker,et al. Influence of 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase inhibitors on endothelial nitric oxide synthase and the formation of oxidants in the vasculature. , 2003, Atherosclerosis.
[20] D. Wysowski,et al. Statin use and the risk of breast cancer. , 2003, Journal of clinical epidemiology.
[21] R. Serra,et al. TGF-β in Mammary Gland Development and Breast Cancer , 2003 .
[22] Kelvin K. W. Chan,et al. The statins as anticancer agents. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[23] K. Bybee,et al. Statin lipid-lowering therapy for acute myocardial infarction and unstable angina: efficacy and mechanism of benefit. , 2002, Mayo Clinic proceedings.
[24] J. Liao. Isoprenoids as mediators of the biological effects of statins. , 2002, The Journal of clinical investigation.
[25] AndrewJ. S. Coats. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial , 2002, The Lancet.
[26] K. Ichihara,et al. Disparity between angiographic regression and clinical event rates with hydrophobic statins , 2002, The Lancet.
[27] L. Esserman,et al. Epithelial and fibroblast cell lines derived from a spontaneous mammary carcinoma in a MMTV/neu transgenic mouse , 2002, In Vitro Cellular & Developmental Biology - Animal.
[28] R. Neve,et al. ErbB2 Activation of ESX gene expression , 2002, Oncogene.
[29] A. Walker,et al. Statin use, hyperlipidaemia, and the risk of breast cancer , 2002, British Journal of Cancer.
[30] Ann G Zauber,et al. Statin Use and the Risk of Breast and Prostate Cancer , 2002, Epidemiology.
[31] David Colquhoun,et al. Long-term effectiveness and safety of pravastatin in 9014 patients with coronary heart disease and average cholesterol concentrations: the LIPID trial follow-up , 2002, The Lancet.
[32] M. Karin,et al. Missing Pieces in the NF-κB Puzzle , 2002, Cell.
[33] E. Sausville,et al. Mining the National Cancer Institute's tumor-screening database: identification of compounds with similar cellular activities. , 2002, Journal of medicinal chemistry.
[34] S. Yusuf. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Commentary , 2002 .
[35] Joerg Kallen,et al. Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site , 2001, Nature Medicine.
[36] J. Deisenhofer,et al. Structural Mechanism for Statin Inhibition of HMG-CoA Reductase , 2001, Science.
[37] Ying Lu,et al. MRI Phenotype Is Associated With Response to Doxorubicin and Cyclophosphamide Neoadjuvant Chemotherapy in Stage III Breast Cancer , 2001, Annals of Surgical Oncology.
[38] Christian A. Rees,et al. Molecular portraits of human breast tumours , 2000, Nature.
[39] L. Blais,et al. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and the risk of cancer: a nested case-control study. , 2000, Archives of internal medicine.
[40] U. Laufs,et al. Direct vascular effects of HMG-CoA reductase inhibitors. , 2000, Trends in cardiovascular medicine.
[41] J. Olsen,et al. Lipid-lowering medication and risk of cancer. , 1999, Journal of clinical epidemiology.
[42] C. Hennekens,et al. Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials. , 1997, JAMA.
[43] A. Qureshi,et al. Isoprenoids suppress the growth of murine B16 melanomas in vitro and in vivo. , 1997, The Journal of nutrition.
[44] P. Macfarlane,et al. West of Scotland Coronary Prevention Study: Identification of high-risk groups and comparison with other cardiovascular intervention trials , 1996 .
[45] B. Davis,et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. , 1996, The New England journal of medicine.
[46] P. Macfarlane,et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia , 1995 .
[47] P. Macfarlane,et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. , 1995, The New England journal of medicine.
[48] R. Cardiff,et al. Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[49] C. Benz,et al. Incidence of activating ras oncogene mutations associated with primary and metastatic human breast cancer. , 1989, Cancer research.